Probiotics and prebiotics play a promising role in managing type 2 diabetes by modulating gut microbiota, which can influence metabolic health. Probiotics, live beneficial bacteria, and prebiotics, non-digestible fibers that feed these bacteria, can improve insulin sensitivity and reduce inflammation, crucial for diabetes control. Studies suggest that certain probiotic strains, like Lactobacillus and Bifidobacterium, enhance gut barrier function and lower blood glucose levels. Prebiotics, such as inulin and fructooligosaccharides, increase short-chain fatty acid production, improving glycemic control. By restoring microbial balance, these interventions may reduce diabetes-related complications, offering a complementary approach to traditional treatments.
Title : Results from a cross-sectional observational study examining irritable bowel syndrome patients six months after finishing their participation in the ViIBS trial
Jacek Piatek, Calisia University, Poland
Title : Gut microbiome as a driver of healthy ageing
Thi Thu Hao Van, RMIT University, Australia
Title : Treating irritable bowel syndrome patients with a balanced multi-strain synbiotic–results from a multi-center, randomized, double-blind, placebo-controlled clinical trial (the ViIBS trial)
Henning Sommermeyer, Calisia University, Poland
Title : Molecular mechanisms underlying the anti-atherogenic actions of probiotics
Dipak P Ramji, Cardiff University, United Kingdom
Title : Global regulatory trends on the use of probiotics and prebiotics in foods and food supplements
David Pineda Ereno, DPE International Consulting, Belgium
Title : Biochemical profile and nutripotential glimpses of Terminalia arjuna bark extract
Suriyavathana Muthukrishnan, Periyar University, India